SEER Inquiry System - Search

First Course Treatment/Neoadjuvant Therapy--Breast: What pathology report descriptions are permissible to use in coding the Neoadjuvant Therapy Treatment Effect data item?  See Discussion.

Solid Tumor Rules/Histology--Lung:  What is the histology code for a lung tumor diagnosed as “Minimally invasive adenocarcinoma, mixed mucinous and non-mucinous, grade 1, lepidic-predominant”?  See Discussion.

First Course Treatment/Surgery of Primary Site--Rectum:  What surgery code should be used for laparoscopic C/T open low anterior resection with colorectal anastomosis, loop ileostomy in diagnosis year 2020, code 30 or 40?  See Discussion.

Solid Tumor Rules/Multiple Primaries--Breast:  Is an in situ tumor followed by an invasive tumor a single or multiple primaries?  See Discussion.

First Course Treatment/Hormone Therapy--Prostate: Is Lupron first course therapy in a patient who initially elected active surveillance for prostate cancer and then consented to treatment with Lupron?  See Discussion.

Histology/Hematopoietic and Lymphoid Neoplasms--AML:  What is the histology code for Acute Myelogenous Leukemia (AML) with monocytic differentiation, 9891/3: acute monoblastic and monocytic leukemia or 9867/3: Acute myelomonocytic leukemia?

Histology/Heme & Lymphoid Neoplasms--Mycosis Fungoides:  What is the histology code for lymphomatoid papulosis that transforms initially to mycosis fungoides (MF)/cutaneous T-cell lymphoma (CTCL) and subsequently to CTCL with large cell transformation, and is it a new primary?  See Discussion.

Reportability/Histology--Gallbladder:  Is intracholecystic papillary-tubular neoplasm (ICPN) with extensive high grade dysplasia of the gallbladder reportable?

Reportability/Histology--Vulva:  Is angiomyxoma (8841/1), such as aggressive angiomyxoma of vulva diagnosed in 2022, reportable?

Update to Current Manual/2018 EOD Manual/EOD Primary Tumor--Bladder: According to the American Joint Commission on Cancer (AJCC), a transurethral resection of the bladder (TURB) cannot make a distinction between involvement of the superficial muscle-inner half (Stage T2a) and the deep muscle-outer half (Stage T2b).  Is this same criteria applied to Extent of Disease (EOD)?